DESLORADENK TABS 5MG 10S

Description

Desloradenk tabs are an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching. It works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction. Available at Rangechem pharmacies country wide. Each tablet contains 5 mg desloratadine.

Therapeutic indications
Desloradenk tabs are indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with:
– allergic rhinitis (see section 5.1)
– urticaria (see section 5.1)
4.2 Posology and method of administration
Posology
Adults and adolescents (12 years of age and over)
The recommended dose of desloratadine is one tablet once a day.
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient’s disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance. In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure periods.
Paediatric population
There is limited clinical trial efficacy experience with the use of desloratadine in adolescents 12 through 17 years of age (see sections 4.8 and 5.1).
The safety and efficacy of Desloradenk tabs 5 mg film-coated tablets in children below the age of 12 years have not been established.
Method of administration
Oral use.
The dose can be taken with or without food.
4.3 Contraindications
Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to loratadine.
4.4 Special warnings and precautions for use
In the case of severe renal insufficiency, desloratadine should be used with caution (see section 5.2).
Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children (see section 4.8), being more susceptible to develop new seizures under desloratadine treatment. Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.